Eagle Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $665K | Buy |
38,857
+11,401
| +42% | +$195K | ﹤0.01% | 500 |
|
|
2024
Q2 | $449K | Buy |
27,456
+841
| +3% | +$13.7K | ﹤0.01% | 537 |
|
|
2024
Q1 | $370K | Buy |
+26,615
| New | +$370K | ﹤0.01% | 547 |
|
|
2021
Q4 | – | Sell |
-17,640
| Closed | -$171K | – | 622 |
|
|
2021
Q3 | $171K | Buy |
17,640
+1,713
| +11% | +$16.6K | ﹤0.01% | 579 |
|
|
2021
Q2 | $157K | Buy |
15,927
+937
| +6% | +$9.24K | ﹤0.01% | 585 |
|
|
2021
Q1 | $172K | Buy |
14,990
+9,087
| +154% | +$104K | ﹤0.01% | 583 |
|
|
2020
Q4 | $56K | Sell |
5,903
-10,319
| -64% | -$97.9K | ﹤0.01% | 539 |
|
|
2020
Q3 | $143K | Sell |
16,222
-466
| -3% | -$4.11K | ﹤0.01% | 559 |
|
|
2020
Q2 | $203K | Buy |
+16,688
| New | +$203K | ﹤0.01% | 550 |
|
|
2019
Q3 | – | Sell |
-18,421
| Closed | -$170K | – | 666 |
|
|
2019
Q2 | $170K | Sell |
18,421
-1,076
| -6% | -$9.93K | ﹤0.01% | 637 |
|
|
2019
Q1 | $305K | Buy |
19,497
+1,427
| +8% | +$22.3K | ﹤0.01% | 593 |
|
|
2018
Q4 | $278K | Buy |
18,070
+3,592
| +25% | +$55.3K | ﹤0.01% | 585 |
|
|
2018
Q3 | $342K | Buy |
+14,478
| New | +$342K | ﹤0.01% | 591 |
|
|
2016
Q4 | – | Sell |
-6,306
| Closed | -$290K | – | 662 |
|
|
2016
Q3 | $290K | Sell |
6,306
-255
| -4% | -$11.7K | ﹤0.01% | 607 |
|
|
2016
Q2 | $329K | Buy |
6,561
+740
| +13% | +$37.1K | ﹤0.01% | 605 |
|
|
2016
Q1 | $311K | Buy |
5,821
+1,133
| +24% | +$60.5K | ﹤0.01% | 601 |
|
|
2015
Q4 | $307K | Buy |
4,688
+727
| +18% | +$47.6K | ﹤0.01% | 613 |
|
|
2015
Q3 | $223K | Buy |
3,961
+186
| +5% | +$10.5K | ﹤0.01% | 632 |
|
|
2015
Q2 | $223K | Buy |
+3,775
| New | +$223K | ﹤0.01% | 634 |
|